Capsid News and Research

RSS

Bristol-Myers Squibb, Prosetta partner to discover and develop new antiviral drugs

Prosetta Antiviral Inc today announced the execution of a strategic alliance with Bristol-Myers Squibb Company to further discover and develop select drug candidates representing new, novel classes of antiviral drugs.

31 Jul 2012

EBV can infect and may also contribute to lymphomas in man's best friend

More than 90 percent of humans have antibodies to the Epstein Barr virus. Best known for causing mononucleosis, or "the kissing disease," the virus has also been implicated in more serious conditions, including Hodgkin's, non-Hodgkin's and Burkitt's lymphomas. Yet little is known about exactly how EBV triggers these diseases.

13 Mar 2012

Scripps Florida receives NIH grant to create novel HIV inhibitors

A Scripps Florida team has been awarded nearly $1.5 million by the National Institutes of Health to identify and develop novel potent inhibitors of the human immunodeficiency virus (HIV), the cause of AIDS.

27 Feb 2012

Tetragenetics reports results from G-SOME H5N1 vaccine preclinical study

Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.

6 Jan 2012

IP-K and Sanofi form new HBV research collaboration

One of the most common and serious infectious diseases, Hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea (IP-K), and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea. The goal is to develop and validate a high throughput assay to screen IP-K's chemical libraries for novel compounds that can be developed as new drugs.

3 Nov 2011

Scientists define structure of astrovirus that causes juvenile diarrhea

Rice University scientists have defined the structure -- down to the atomic level -- of a virus that causes juvenile diarrhea. The research may help direct efforts to develop medications that block the virus before it becomes infectious.

19 Jul 2011

Researchers identify altered expression of endogenous retroviruses in BSE-infected macaques

Prion diseases such as Creutzfeldt-Jakob disease in humans and bovine spongiform encephalopathy (BSE) in cattle are transmissible neurodegenerative diseases linked to the aggregation of the prion protein in the central nervous system.

1 Jul 2011

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Scientists have shown that an experimental vaccine against the human norovirus - the bug behind about 90 percent of highly contagious nonbacterial illnesses that cause diarrhea and vomiting - can generate a strong immune response in mice without appearing to cause the animals any harm.

16 Mar 2011

Scientists determine protein structure that delivers genetic material of HIV to human cells

A team of scientists at The Scripps Research Institute and the University of Virginia has determined the structure of the protein package that delivers the genetic material of the human immunodeficiency virus to human cells.

19 Jan 2011

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.

29 Dec 2010

Scientists find potential Achilles Heel in JC polyomavirus

The JC polyomavirus doesn't strike very often, but it's a mean bug that preys on people with weakened immune systems, including people with AIDS, and almost always kills them. Now an international team of scientists at Brown University, the University of T-bingen in Germany, and Imperial College in London has found a potential Achilles Heel and painted a target on it: The virus must bind to a very specific sugar molecule dangling from the side of the brain cells it attacks.

21 Oct 2010

LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company focused on the development of innovative vaccine products, announced today that it has initiated the first clinical trial for its bivalent intramuscular (IM) norovirus vaccine candidate, marking the fourth human clinical trial in the Company's norovirus virus-like particle (VLP) vaccine program.

17 Sep 2010

Scientists discover sensor in dendritic cells that recognizes HIV

Dendritic cells are the grand sentinels of the immune system, standing guard 24/7 to detect foreign invaders such as viruses and bacteria, and bring news of the invasion to other immune cells to marshal an attack. These sentinels, however, nearly always fail to respond adequately to HIV, the virus causing AIDS. Now a team of scientists at NYU Langone Medical Center has discovered a sensor in dendritic cells that recognizes HIV, spurring a more potent immune response by the sentinels to the virus.

9 Sep 2010

Trigger that induces B cells to produce early, effective antibody response discovered

Researchers at National Jewish Health have discovered a trigger that induces B cells to produce effective and long-lived antibodies early in the immune response. They found that a molecule that binds toll-like receptors doubles the early antibody response to an antigen, and shifts it to a more effective, IgG form.

7 Jul 2010

New research may help advance treatment strategies for common liver disease

A research article published in the journal PloS Pathogens could lead to improvements in the production of vaccines for hepatitis A, the most widespread viral disease in the world.

26 Mar 2010

Third human clinical trial of LigoCyte's norovirus vaccine started

LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.

8 Sep 2009

Structure of the HIV protein shell revealed

New research by scientists at The Scripps Research Institute and other institutions provides a close-up look at the cone-shaped shell that is the hallmark of human immunodeficiency virus (HIV), revealing how it is held together - and possible ways to break it apart.

13 Jun 2009